Advertisements



Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients

Japan has one of the highest rates of hepatitis C in the industrialized worldRelated Stocks: ENTA, ABBV,.....»»

Category: worldSource: nytJan 11th, 2017

Novartis Buys Selexys on Favorable Phase II Data on SelG1

Novartis (NVS) acquired Selexys Pharmaceuticals following the receipt of results from the phase II SUSTAIN study for the treatment of patients with SCD. Swiss drug maker Novartis AG NVS announced that it has acquired Selexys Pharmaceuticals Cor.....»»

Category: topSource: zacksNov 22nd, 2016

AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb

AbbVie Inc. (ABBV) announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax and Exviera for the treatment of patients with hepatitis C virus (HCV) infection without liver cirrhosis. AbbVie I.....»»

Category: topSource: zacksSep 26th, 2016

Alexion (ALXN) Reports Interim Results for Soliris Study

Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory gener.....»»

Category: smallbizSource: nytSep 14th, 2017

Marinus Pharma Wins Big With Mid-Stage Epilepsy Study

Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder......»»

Category: blogSource: 247wallstSep 11th, 2017

Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective

Eli Lilly & Co. said early Friday that its migraine prevention drug had positive results in a late-stage, 12-month open-label study. The therapy, galcanezumab, showed a positive safety and tolerability profile in patients, the company said, and wa.....»»

Category: topSource: marketwatchSep 8th, 2017

Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results

- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH ­-             - Raised $35 million f.....»»

Category: earningsSource: benzingaAug 10th, 2017

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results

RESULT, pivotal Phase 3 study of Sollpura began screening patients in the .....»»

Category: earningsSource: benzingaAug 9th, 2017

Paratek Antibiotic Candidate"s Phase III Data Favorable

Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial.....»»

Category: topSource: zacksJul 18th, 2017

Why Ionis Results Today Support A Pair Trade With Alnylam

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneur Latest Ratings for ALN.....»»

Category: blogSource: benzingaMay 15th, 2017

ResMed"s Study Results for Central Sleep Apnea Hold Promise

ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). Medical device c.....»»

Category: topSource: zacksApr 11th, 2017

ANTH"s (ANTH) Blisibimod Completes Dosing in Phase III Study

Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN.....»»

Category: topSource: zacksApr 11th, 2017

Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) nearly half its value Tuesday following the release of interim results of its Phase 1 study of CPI-444, designed to treat patients with advanced cancers. Latest Ratings for CRV.....»»

Category: blogSource: benzingaApr 5th, 2017

Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate

Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients. Sp.....»»

Category: topSource: zacksMar 31st, 2017

How La Jolla’s Low Blood Pressure Treatment Is Driving New Highs

La Jolla Pharmaceutical saw its shares skyrocket on Monday after top-line results from its late-stage study of patients with catecholamine resistant hypotension......»»

Category: blogSource: 247wallstFeb 27th, 2017

Catabasis shares plummet on Duchenne trial failure

Cambridge-based Catabasis Pharmaceuticals is poised to lose most of its market value after announcing disappointing results from a study of its Duchenne muscular dystrophy treatment late Tuesday. Catabasis (Nasdaq: CATB), which had 37 employees t.....»»

Category: topSource: bizjournalsJan 31st, 2017

Marinus Releases Positive Preliminary Data from CDKL5 Study

Marinus Pharmaceuticals, Inc. (MRNS), announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study.....»»

Category: topSource: zacksJan 24th, 2017

Pfizer"s Humira Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis. .....»»

Category: topSource: zacksJan 6th, 2017

Triad firm reports positive results for study of diabetes treatment

High Point-based biopharmaceutical company vTv Therapeutics Inc. announced that it has completed a successful phase 2 study that evaluated its oral therapy used to treat Type 2 diabetes patients. The 12-week study conducted across 30 centers in the U.S. .....»»

Category: topSource: bizjournalsDec 16th, 2016

Cambridge gene therapy firm Voyager gets positive results on Parkinson"s treatment

A Parkinson’s treatment developed by Cambridge gene therapy firm Voyager Therapeutics helped patients improve motor function in a small, early-stage study, the company said Wednesday. Voyager (Nasdaq: VYGR), part of a new wave of gene editing firms in .....»»

Category: topSource: bizjournalsDec 7th, 2016

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures. P.....»»

Category: topSource: zacksDec 2nd, 2016